•  

    LIFE SCIENCES

    Our main motivation is research and production of innovative and affordable drugs for patients.

  •  

    LIFE SCIENCES

    Our main motivation is research and production of innovative and affordable drugs for patients.

     

  •  

    LIFE SCIENCES

    Our main motivation is research and production of innovative and affordable drugs for patients.

     

  •  

    LIFE SCIENCES

    Our main motivation is research and production of innovative and affordable drugs for patients.

     

 

Global Network for the Production of Medicines

The pharmaceutical industry is our initial activity, and the most important one, as it represents 80% of our revenues. It includes three companies: Chemo, the Group’s first company, focusing on the production of pharmaceutical ingredients and generics; Exeltis, a company that manufactures and markets branded medicines, and mAbxience, a producer of biosimilars.

In Argentina, we are shareholders of pharmaceutical companies Elea, Biogénesis Bagó, Sinergium Biotech, Chemotécnica S.A. and Inmunova.

Research, development and production of innovative medicines with the highest quality standards have been our main motivations from the start, and the driving forces behind our thriving global presence.

Insud Pharma

Covering all the links of the chemical-pharmaceutical industry. We have 3 business areas of action and a common base in R&D to develop new and better therapeutic solutions.

+

Biogenesis Bagó

A regional biotechnology company engaged in the research, development, manufacturing and marketing of veterinary products and services, to improve the health and productivity of beef and dairy cattle.

+

Our Group, through its company Chemo, has nine R&D centers worldwide. Our corporate R&D Headquarters, Chemessentia, researches and develops processes for the production of active pharmaceutical ingredients. It is located in Novara, Italy.

Our R&D Center Ladee Pharma Research Institute (LPRI), located in Spain, is devoted to scientific research and production of finished products and new pharmaceutical formulations for a range of therapeutic areas.

At present, we have an IT platform for research, development and production of monoclonal antibodies.

As a Group, we have a commitment to work as a network in order to build connections enabling us to make new discoveries and facilitating technology transfer to help patients access quality medicines.

+ Read More.